During the month of May, the Cartridge and Propellant Actuated Device (CAD/PAD) Joint Program supported two workshops sponsored by NAVAIR's Program Management Air (PMA) 201 at the College of Southern ...
In April, an ejection seat manufacturer officially notified the Naval Surface Warfare Center Indian Head Division (NSWC IHD) Cartridge Actuated Devices/Propellant Actuated Devices (CAD/PAD) Joint ...
Janssen announced that the Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) ...
Please provide your email address to receive an email when new articles are posted on . The Foundation to Advance Vascular Cures has launched a new virtual educational resource directed at medical ...
Rivaroxaban is the first and only non–vitamin K antagonist oral anticoagulant with this indication, the company said in a news release. The European Commission approved a regimen of rivaroxaban plus ...
Patients who have both coronary and peripheral artery disease experience consistent reductions in ischemic complications after coronary stent placement when treated with extended dual antiplatelet ...